Last reviewed · How we verify
D326
D326 is a small molecule drug that targets the SGLT2 receptor.
D326 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | D326 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, D326 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg (PHASE1)
- Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg (PHASE1)
- Clinical Trial to Evaluate the Efficacy and Safety of CKD-386 (PHASE3)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386 (PHASE1)
- Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D326 CI brief — competitive landscape report
- D326 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI